| 前收市價 | 60.50 |
| 開市 | 60.50 |
| 買盤 | 78.00 |
| 賣出價 | 82.50 |
| 拍板 | 100.00 |
| 到期日 | 2024-12-20 |
| 今日波幅 | 57.50 - 60.50 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2 |
Barrons.comResMed Stock Is Sinking. Blame Lilly’s Zepbound Trials for Sleep Apnea.
Eli Lilly is seeking FDA approval to expand the uses for its weight-loss drug Zepbound to include sleep apnea.
ZacksIDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.
ZacksQuest Diagnostics (DGX) Gains From New M&As Amid Competition
In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.
